PEG-MGF
also known as Pegylated Mechano Growth Factor, PEG-Mechano Growth Factor, IGF-1Ec-PEG
PEGylated variant of mechano growth factor (MGF / IGF-1Ec), a splice variant of IGF-1 upregulated by mechanical loading. Polyethylene glycol conjugation extends plasma half-life from ~7 minutes (native MGF) to approximately 2 hours. Research application targets satellite cell activation, muscle repair, and post-exercise recovery. Not FDA-approved; limited to preclinical and mechanistic studies.
At a glance
SQ · Research Protocol
Primary target — IGF-1 receptor on muscle satellite cells and myocytes.
Pathway — IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion.
Downstream effect — Satellite cell activation, muscle fiber repair, localized hypertrophy signaling.
Origin — IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation.
Feedback intact — Partially bypassed — does not require hepatic IGF-1 synthesis.
| Parameter | Value |
|---|---|
| Research dose range | 100–200 mcgExtrapolated from animal models; no validated human protocols. |
| Frequency | Post-training or dailyTiming to match endogenous MGF pulse post-exercise. |
| Half-life | ~2 hours (PEGylated)Native MGF: ~7 min; PEGylation extends circulation. |
| Evidence basis | Animal / mechanistic |
| Reconstitution | Sterile bacteriostatic waterLyophilized form; store reconstituted at 2–8 °C. |
| PEG molecular weight | Typically 5–30 kDaHigher MW = longer t½, greater steric hindrance. |
| Timing | Within 30–60 min post-trainingAligns with endogenous MGF window. |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
IGF-1 axis implicated in metabolic regulation; PEG-MGF primarily studied for muscle repair, not adipose targeting
| Outcome | Finding |
|---|---|
| Primary target | Muscle tissue (satellite cells, myocytes) — not adipose-specific |
| Indirect metabolic effect | IGF-1 signaling may modulate insulin sensitivity and lipid metabolism [ren-2015]Mechanism distinct from direct lipolytic peptides. |
| Body composition | Lean mass preservation / hypertrophy focus |
| Fat loss evidence | No direct human or animal RCT data for PEG-MGF-driven fat reduction |
- — Active malignancy or history of cancer (IGF-1R proliferative signaling)
- — Known hypersensitivity to PEGylated compounds
- — Pregnancy / lactation (no reproductive toxicity data)
- — Diabetes (monitor glucose closely)
- — Renal impairment (PEG clearance reduced)
- — Retinopathy (IGF-1 axis effects on vascular proliferation)
- 01Reconstitution
Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.
- 02Injection site
Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.
- 03Timing
Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.
- 04Storage
Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.
- 05Needle
29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.
BPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.
TB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.
Sources
of 69 rendered claims carry a resolvable citation.
- [braun-2018]Braun 2018 — Bioresponsive release of insulin-like growth factor-I from its PEGylated conjugate.
journal, 2018 - [ren-2015]Ren 2015 — The insulin-like growth factor I system: physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome.
journal, 2015